Methicillin-resistant Staphylococcus Aureus Drugs Market Analysis

Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

In methicillin-resistant staphylococcus aureus drugs market, hospital pharmacy segment is poised to dominate around 50% share by the end of 2036. This could be owing to the rising number of hospitals in this region. The total number of hospitals around the globe as of 2021 is projected to be about 164,000. Furthermore, hospitals are the exclusive partners with hospital-based reference laboratories for methicillin-resistant staphylococcus aureus drugs.

Due to the huge volume of patients, lengthy turnaround times, and high costs associated with hospitals, only a small number of complex tests are referred to these laboratories. These labs use skilled laboratory professionals and state-of-the-art equipment to handle the large volume of tests. Clinical research, disease surveillance programs, monitoring response to treatment, and disease diagnosis all depend significantly on hospitals and diagnostic labs.

Timely and timely intervention is made feasible by diagnostic techniques, which lowers the impact of disease and improves health. The medication needed for MRSA is determined using the information gathered from patient samples. As a result, the segment will have steady growth in methicillin-resistant staphylococcus aureus drugs market.

Drug Class (Lipopeptide, Oxazolidine, Tetracycline, Cephalosporin, Lipoglycopeptide, Folate Antagonist

In methicillin-resistant staphylococcus aureus drugs market, lipopeptide segment is estimated to capture over 30% revenue share by 2036. This may be due to lipopeptides including daptomycin that have a well-established market due to effective global distribution by producers and distributors. Newly developed lipopeptide antibiotic daptomycin is bactericidal against a variety of gram-positive isolates when delivered intravenously.

It exhibits quick, dependent on concentration bactericidal action against isolates that are vulnerable, such as MRSA. Although complex urinary tract infections are also treated with it, gram-positive bacterial skin and soft tissue infections are the main indications for its usage. 

Our in-depth analysis of the Global Market Includes the following segments: